抑制PDE4D可以通过激活线粒细胞衰竭来改善心脏缩和心力衰竭
Jing Fu1, Congping Su2, Yin Ge2
1Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of Pharmacy, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Redox biology
|February 27, 2025
概括
持续的上腺刺激会增加PDE4D,通过抑制线粒细胞衰竭,导致心力衰竭. 抑制PDE4D可能为心力衰竭提供一种新的治疗策略.
科学领域:
- 心血管生物学 心血管生物学
- 分子心脏病学分子心脏病学
- 生物化学 生物化学
背景情况:
- 循环腺单酸盐 (cAMP) 在心脏信号传递中至关重要,化酶4 (PDE4) 调节其水平.
- 在心脏功能和心力衰竭 (HF) 中,PDE4异型,特别是PDE4B和PDE4D的作用尚未完全理解.
- 现有研究表明,在高频调节中,PDE4B和PDE4D的结果相矛盾.
研究的目的:
- 研究PDE4D在心脏缩和心力衰竭 (HF) 中的特定作用.
- 阐明PDE4D影响心肌细胞功能和线粒体健康的分子机制.
- 评估PDE4D抑制在高频率中的治疗潜力.
主要方法:
- 产生了全球性和心脏特异性的异构体PDE4D淘汰赛小鼠和PDE4D过度表达的小鼠.
- 使用了体外心肌细胞模型与异二醇刺激和体内模型,包括异二醇注射和横向大动脉收缩 (TAC).
- 评估了心脏功能,缩,线粒体损伤,线粒体和信号通路 (cAMP-PKA-CREB-Sirtuin1).
主要成果:
- 在失败的人和小鼠的心脏中,PDE4D被上调;通过抑制通过cAMP-PKA-CREB-Sirtuin1通路的线粒细胞衰变,其过度表达诱导了过度缩和线粒体功能障碍.
- 过度表达PDE4B在心肌细胞中显示了保护性作用,防止心肌细胞过度缩小和氧化应激.
- 抑制或沉默PDE4D,或PDE4D平分不足,改善心脏缩和肝炎症状体内,而PDE4D过度表达加剧了这些情况.
结论:
- 持续的上腺刺激通过上调PDE4D促进心脏缩和心脏缩,这会通过cAMP-PKA-CREB-Sirtuin1通路损害线粒.
- 抑制PDE4D证明了治疗心脏缩和心力衰竭的治疗潜力.
- 在持续的上腺体信号传递下,PDE4D而不是PDE4B在HF进展中起着有害的作用.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
363
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
363
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:22Heart Failure Drugs: Diuretics
324
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
324
01:22Heart Failure Drugs: β-Blockers
306
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
306
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
124
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
124